{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:28:58Z","timestamp":1774949338167,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.gastrohep.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T02:52:44Z","timestamp":1531536764000},"page":"458-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Revisando el papel terap\u00e9utico de la budesonida en la enfermedad de Crohn"],"prefix":"10.1016","volume":"41","author":[{"given":"Antonio","family":"L\u00f3pez-Sanrom\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Clofent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Garcia-Planella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Mench\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Nos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iago","family":"Rodr\u00edguez-Lago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugeni","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2018.05.013_bib0425","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14656566.2016.1183648","article-title":"Budesonide for the treatment of ulcerative colitis","volume":"17","author":"Abdalla","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0430","first-page":"74","article-title":"Topical and systemic glucocorticoid potencies of budesonide, beclomethasone, dipropionate and prednisolone in man","volume":"122","author":"Johansson","year":"1982","journal-title":"Eur J Respir Dis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0435","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0440","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90233-9","article-title":"Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function","volume":"63","author":"Meikle","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0445","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-9556(25)06716-9","article-title":"Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects","volume":"15","author":"Edsb\u00e4cker","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0450","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.addr.2004.08.009","article-title":"Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide","volume":"57","author":"Fedorak","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0455","unstructured":"Ficha t\u00e9cnica de Entocord\u00ae 3mg c\u00e1psulas de liberaci\u00f3n modificada. Revisi\u00f3n octubre 2012 [consultado 29 Jun 2018]. Disponible en: https:\/\/www.aemps.gob.es\/cima\/pdfs\/es\/ft\/61728\/61728_ft.pdf"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0460","unstructured":"Ficha t\u00e9cnica de Intestifalk\u00ae 3mg c\u00e1psulas de liberaci\u00f3n modificada. Revisi\u00f3n mayo 2017 [consultado 29 Jun 2018]. Disponible en: https:\/\/www.aemps.gob.es\/cima\/pdfs\/es\/ft\/65849\/65849_ft.pdf"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0465","unstructured":"European Medicines Agency (EMA). Budesonide [consultado 20 Feb 2017]. Disponible en: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages%2Fincludes%2Fmedicines%2Fmedicines_landing_page.jsp&searchkwByEnter=true&quickSearch=budesonide&spanFlag=0&keywordSearch=Submit"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0470","unstructured":"FDA Approved Drug Products [consultado 20 Feb 2017]. Disponible en: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=browseByLetter.page&productLetter=B&ai=0"},{"issue":"4 Suppl 1","key":"10.1016\/j.gastrohep.2018.05.013_bib0475","article-title":"Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules [abstract]","volume":"104","author":"Edsb\u00e4cker","year":"1993","journal-title":"Gastroenterology"},{"issue":"Suppl 5","key":"10.1016\/j.gastrohep.2018.05.013_bib0480","doi-asserted-by":"crossref","first-page":"V1","DOI":"10.1136\/gut.2004.043372","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"53","author":"Carter","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0485","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn's disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0490","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0495","first-page":"46","article-title":"Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation","volume":"82","author":"Yamamoto-Furusho","year":"2017","journal-title":"Rev Gastroenterol Mex"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0500","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.dld.2016.12.008","article-title":"French national consensus clinical guidelines for the management of Crohn's disease","volume":"49","author":"Peyrin-Biroulet","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2018.05.013_bib0505","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/MPG.0b013e3181c92caa","article-title":"Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease","volume":"50","author":"Wilson","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0510","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/archdischild-2014-307217","article-title":"Management of Crohn's disease","volume":"101","author":"Kammermeier","year":"2016","journal-title":"Arch Dis Child."},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0515","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000296.pub4","article-title":"Budesonide for induction of remission in Crohn's disease","author":"Rezaie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0520","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2165\/00003495-200262150-00015","article-title":"Budesonide (Entocort EC Capsules): A review of its therapeutic use in the management of active Crohn's disease in adults","volume":"62","author":"McKeage","year":"2002","journal-title":"Drugs."},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0525","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0530","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","article-title":"Budesonide CIR capsules (once or twice daily divided doses) in active Crohn's disease: A randomized placebo-controlled study in the United States","volume":"97","author":"Tremaine","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0535","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","article-title":"Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: A multicentre, double-blind, randomized, parallel-group Phase II study","volume":"7","author":"Suzuki","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0540","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0545","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","article-title":"Budesonide 9mg is at least as effective as mesalamine 4.5g in patients with mildly to moderately active Crohn's disease","volume":"140","author":"Tromm","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0550","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Global Budesonide Study Group","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0555","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0560","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: Clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0565","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2174\/1389450115666140821113330","article-title":"Management of inflammatory bowel disease patients with a cancer history","volume":"15","author":"Beaugerie","year":"2014","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0570","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/apt.13190","article-title":"Systematic review with network meta-analysis: Comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease","volume":"41","author":"Moja","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0575","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0580","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1185\/030079905X50570","article-title":"A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide","volume":"21","author":"Gluck","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0585","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ibd.20640","article-title":"Budesonide induction and maintenance therapy for Crohn's disease during pregnancy","volume":"15","author":"Beaulieu","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0590","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"Van der Woude","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0595","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0600","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.MIB.0000192323.82426.83","article-title":"Budesonide in the treatment of inflammatory bowel disease: The first year of experience in clinical practice","volume":"12","author":"Chopra","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0605","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1365-2036.2007.03306.x","article-title":"Oral budesonide in the treatment of chronic refractory pouchitis","volume":"25","author":"Gionchetti","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0610","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1157\/13127089","article-title":"[Oral budesonide in the treatment of chronic refractory pouchitis]","volume":"31","author":"Cabriada Nu\u00f1o","year":"2008","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0615","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.crohns.2011.10.011","article-title":"Impact of budesonide on liver function tests and gut inflammation in patients with primary sclerosing cholangitis and ileal pouch anal anastomosis","volume":"6","author":"Navaneethan","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0620","article-title":"Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of tiopurines in inflammatory bowel disease","author":"Bermejo","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0625","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: Loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn's disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0630","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/ecco-jcc\/jjx149","article-title":"A role for thiopurine metabolites in the synergism between thiopurines and infliximab in inflammatory bowel disease","volume":"12","author":"Mogensen","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0635","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ecco-jcc\/jjx144","article-title":"Anti-TNF re-induction is as effective, simpler and cheaper compared with dose-interval shortening for secondary loss of response in Crohn's disease","volume":"12","author":"Srinivasan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0640","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.gastro.2014.09.031","article-title":"Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: A systematic review and network meta-analysis","volume":"148","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0645","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0016-5085(99)70125-3","article-title":"Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group","volume":"116","author":"Hellers","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0650","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00042737-199903000-00011","volume":"11","author":"Ewe","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0655","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10350-004-0768-8","article-title":"Long-term treatment of high intestinal output syndrome with budesonide in patients with Crohn's disease and ileostomy","volume":"248","author":"Ecker","year":"2005","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0660","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/00365520310000645a","article-title":"Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn disease","volume":"38","author":"Ecker","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0665","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1007\/s00246-011-0029-2","article-title":"Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients","volume":"32","author":"Schumacher","year":"2011","journal-title":"Pediatr Cardiol."},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0670","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.48.2.186","article-title":"Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease","volume":"48","author":"Cortot","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0675","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/cgh.2003.50015","article-title":"Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease","volume":"1","author":"Mantzaris","year":"2003","journal-title":"Clin Gastro Hepatol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0680","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00042737-199810000-00001","article-title":"Clinical pattern of corticosteroid dependent Crohn's disease","volume":"10","author":"Franchimont","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0685","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/ibd.21608","article-title":"Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with Crohn's disease","volume":"17","author":"Krupoves","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0690","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/1994\/956865","article-title":"Budesonide for the treatment of inflammatory bowel disease","volume":"8","author":"Greenberg","year":"1994","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0695","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study","volume":"39","author":"L\u00f6fberg","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0700","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","article-title":"Budesonide as maintenance treatment in Crohn's disease: A placebo-controlled trial","volume":"21","author":"Hanauer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0705","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","article-title":"Oral budesonide as maintenance therapy in Crohn's disease-results of a 12-month study. Global Budesonide Study Group","volume":"12","author":"Ferguson","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0710","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1046\/j.1365-2036.2001.01055.x","article-title":"Maintenance of Crohn's disease over 12 months: Fixed versus flexible dosing regime using budesonide controlled ileal release capsules","volume":"15","author":"Green","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0715","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00384-003-0529-5","article-title":"Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization","volume":"19","author":"Herfarth","year":"2004","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0720","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1572-0241.2005.41992.x","article-title":"Budesonide for maintenance of remission in patients with Crohn's disease in medically-induced remission: A predetermined pooled analysis of 4randomized, double-blind, placebo-controlled trials","volume":"100","author":"Sandborn","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0725","first-page":"339","article-title":"Maintenance treatment with budesonide 6mg versus 9mg 11daily in patients with Crohn's disease in remission","volume":"65","author":"De Jong","year":"2007","journal-title":"Neth J Med"},{"issue":"11-12","key":"10.1016\/j.gastrohep.2018.05.013_bib0730","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1365-2036.2005.02688.x","article-title":"Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide","volume":"22","author":"Miehlke","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0735","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1053\/j.gastro.2008.07.081","article-title":"Oral budesonide for maintenance treatment of collagenous colitis: A randomized, double-blind, placebo-controlled trial","volume":"135","author":"Miehlke","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0740","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1365-2036.2002.01289.x","article-title":"The effectiveness of budesonide therapy for Crohn's disease","volume":"16","author":"Kane","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0745","article-title":"Budesonide for maintenance of remission in Crohn's disease","volume":"8","author":"Kuenzig","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0750","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2007.03455.x","article-title":"Medical management of mild to moderate cron's disease: Evidence-based treatment algorithms for induction and maintenance of remission","volume":"26","author":"Sandborn","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0755","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00054725-200008000-00004","volume":"6","author":"Irvine","year":"2000","journal-title":"Inflam Bowel Dis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0760","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ibd.20881","article-title":"Comparison of 2dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: A randomized placebo-controlled trial","volume":"15","author":"Levine","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0765","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212216","article-title":"Budesonide-related adrenal insufficiency","author":"Arntzenius","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0770","first-page":"803","article-title":"Pharmacokinetics of budesonide (Entocord EC) capsules for Crohn's disease","volume":"43","author":"Edsb\u00e4cker","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0775","unstructured":"Australian Goverment, Department of Health and Aging. Therapeutic goods administration. Australian public asssesment report for budesonide. October 2012 [consultado 20 Feb 2018]. Disponible en: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-budesonide-121022-1.pdf"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0780","unstructured":"Association \u2018Inititative on Crohn and Colitis\u2019. Richtlijn diagnostiek en behandeling van inflammatoire darmziekten bij volwassenen, Nederlandse Vereniging van Maag-DarmLeverartsen. Haarlem [consultado 20 Feb 2018]. Disponible en: http:\/\/www.icc-ibd.com\/home\/en"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0785","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0790","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/gast.2003.50106","article-title":"AGA technical review on osteoporosis in gastrointestinal diseases","volume":"124","author":"Bernstein","year":"2003","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.gastrohep.2018.05.013_bib0795","article-title":"Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease","volume":"46","author":"Scott","year":"2000","journal-title":"British Society of Gastroenterology. Gut"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0800","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0805","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0810","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1572-0241.2002.05609.x","article-title":"Bone mineral density in Crohn's disease: A longitudinal study of budesonide, prednisone, and nonsteroid therapy","volume":"97","author":"Cino","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0815","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1365-2036.1996.63205000.x","article-title":"Bone mineral density in Crohn's disease: A longitudinal study of budesonide, prednisone, and nonsteroid therapy","volume":"10","author":"Bernstein","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0820","first-page":"570","article-title":"Meta-analyses of therapies for posmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for posmenopausal osteoporosis. Endocr Rev","volume":"23","author":"Cranney","year":"2002"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0825","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","article-title":"Vitamin D3 and calcium to prevent hip fractures in elderly women","volume":"327","author":"Chapuy","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0830","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","article-title":"Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older","volume":"337","author":"Dawson-Hughes","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0835","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.291.16.1999","article-title":"Effect of Vitamin D on falls: A meta-analysis","volume":"291","author":"Bischoff-Ferrari","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.gastrohep.2018.05.013_bib0840","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1210\/en.2003-1096","article-title":"Muscle: A nontraditional 1,25- dihydroxyvitamin D target tissue exhibiting classic hormone-dependent vitamin D receptor actions","volume":"144","author":"Demay","year":"2003","journal-title":"Endocrinology"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570518301444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570518301444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T20:00:55Z","timestamp":1751745655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570518301444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0210570518301444"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2018.05.013","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisando el papel terap\u00e9utico de la budesonida en la enfermedad de Crohn","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}